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Long-term efficacy of imatinib 
mesylate in patients with advanced 
Tenosynovial Giant Cell Tumor
F. G. M. Verspoor  1, M. J. L. Mastboom2, G. Hannink3, R. G. Maki  4, A. Wagner  5, 
e. Bompas6, J. Desai  7, A. Italiano8, B. M. Seddon9, W. T. A. van der Graaf10, J.-Y. Blay  11, 
M. Brahmi11, L. Eberst11, S. Stacchiotti12, o. Mir13, M. A. J. van de Sande2, H. Gelderblom14 & 
p. A. Cassier  11
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative 
disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences 
necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study 
investigated the long term effects of IM in TGCT. We conducted an international multi-institutional 
retrospective study to assess the activity of IM: data was collected anonymously from individual 
patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions 
across Europe, Australia and the United States were identified. Four patients with metastatic TGCT 
progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients 
achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival 
rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 
7 (range 1–80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) 
and fatigue (50%), mostly grade 1–2 (89%). Five patients experienced grade 3–4 toxicities. This study 
confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed 
prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment 
interruption and additional treatments.
Tenosynovial giant-cell tumor (TGCT), historically known as pigmented villonodular synovitis (PVNS), is a rare, 
at times locally aggressive neoplasm affecting the joints or tendon sheaths in young adults. It is most common 
around large joints such as the knees, ankles and hips1,2. Known subtypes are localized and diffuse TGCT. The 
localized subtype comprises a single nodule and has a favorable course while the diffuse subtype involves the 
synovial lining as well as surrounding structures and is associated with a significant risk of recurrence (>50% 
depending on follow up times), despite being a benign neoplasm2–4. Metastatic forms have been described, but 
seem to occur very rarely5,6.
Surgical resection is the primary treatment for both subtypes. However, diffuse TGCT is difficult to remove 
completely and often requires a total synovectomy, or at times a joint replacement, or rarely even amputation1,2,7. 
In patients with extensive and/or recurrent TGCT, other available treatment modalities include radiation 
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synovectomy8, external beam radiation therapy9, and cryosurgery10. Their therapeutic value has only been 
assessed in retrospective, in most cases single center series and their long term side effects and complications are 
poorly described11.
Recurrent TGCT is rarely lethal, but frequently becomes a debilitating chronic illness with substantial morbid-
ity to the joints and quality of life impairment, caused by the disease itself and the multiple treatments2,12.
In TGCT, a neoplastic clone constitutes a subpopulation (2–16%)13 of cells that overexpress colony-stimulating 
factor-1 (CSF-1). A t(1;2) translocation that links the CSF1 gene on chromosome 1p13 to the COL6A3 gene on 
chromosome 2q35 has been described and is believed to be responsible for the overproduction of CSF1 by neo-
plastic cells13,14. Inhibition of CSF1/CSF-1 receptor (CSF-1R) signaling has shown efficacy in the treatment of 
locally advanced and recurrent diffuse TGCT15–17.
Imatinib mesylate (IM) inhibits the CSF-1R kinase among other kinases17. It has been shown that inhibition 
of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nmol/L18. We have previously reported on 
the efficacy of IM in TGCT. In the present study we provide long term follow-up on these initial patients and data 
on 33 additional consecutive patients.
Methods
This retrospective study was conducted at 12 referral centers across Europe (9 institutions), the United States of 
America (2 institutions), and Australia (1 institution). The file of all patients with locally advanced, recurrent or 
metastatic TGCT, treated with IM were reviewed. Patient information was extracted from individual patients’ 
files at each institution by the local investigators and was provided in an anonymous form for final analyses. 
Histopathologic examination was performed at center of origin by pathologists with extensive experience in 
mesenchymal tumors. Response was measured using version 1.0 of Response Evaluation Criteria in Solid Tumors 
(RECIST). Data were described using percentages for qualitative variables and medians with ranges for contin-
uous variables.
Patients were not treated following a fixed regimen. The study protocol and retrospective analysis was 
approved by the Ethics Committee in Lyon (Committee for the Protection of Individuals, Sud-Est IV, Lyon, 
France – L10-153 dated 9 December 2010) and was carried out in accordance with the applicable rules con-
cerning the review of research ethics committees. Patients provided written informed consent to treatment with 
‘off-label’ medication, for research review and analysis of medical records. Treatment decision was left to the 
treating physician. The study was conducted in accordance with ethical requirements that differed per country. 
National investigators dealt with it according to standard practice. All 12 centers at which the study was carried 
out approved access to the data.
Survival was plotted using the Kaplan-Meier method. Progression-free survival (PFS) was calculated from 
the date IM was started to the date of disease progression or death. The time to treatment failure (TTF) was cal-
culated from the date IM was started to the date it was stopped because of toxicity, disease progression, or death, 
whichever occurred first. For patients with a surgical resection or other additional therapy after treatment with 
IM, PFS and TTF were censored at the time of surgery. Disease specific survival was calculated from the date IM 
was started to the date of death due to TGCT. Symptomatic response was defined as improvement of pain and/or 
joint function in patients who had symptoms at baseline. All statistical analyses were performed using R version 
3.4.0 (R Foundation, Vienna, Austria) with packages ‘ggplot2’, ‘rms’, and ‘survival’.
Results
Patients. A total of 62 patients with histopathologically proven TGCT treated with imatinib were identified, 
their main characteristics are described in Table 1. Briefly, median age at diagnosis was 39 (interquartile range 
(IQR) 31–53) years and 45 (IQR 36–56) years at start of treatment with IM, the majority of patients were female 
(N = 39, 63%), and the knee (N = 35, 56%) was the most commonly affected joint (Table 1). At start of IM treat-
ment, three (5%) patients had biopsy proven metastatic disease, 15 (24%) locally advanced disease and 44 (71%) 
locally recurrent disease. Among patients with prior operations for TGCT (n = 47), the median number of prior 
operations was 2 (range 1–9), and the time since the last operation was 23 (range 1–192) months. Median follow 
up of all patients was 52 (IQR 18–83) months.
Treatment efficacy. Sixty-one patients received 400 mg and one patient received 600 mg IM daily, all as 
a single dose/day. The 3 patients with metastatic disease at treatment start progressed rapidly on IM and were 
excluded from further analysis. One other patient with metastatic disease after multiple surgical treatments and 
IM, was excluded for further analyses too, leaving 58 patients for the rest of the analysis.
Median duration of IM treatment was 9 (IQR 5–27) months. At last follow-up, the majority of patients (n = 38; 
66%) had discontinued treatment. Seventy-seven percent (95% CI 67–89), 41% (95% CI 29–57) and 36% (95% 
CI 25–52) of patients were still on IM after 6-, 12- and 24-months, respectively (Fig. 1). The treatment failure-rate 
was 18% (95% CI 6–29) after 12 months.
Response could not be assessed in 3 patients, two of which were lost to follow-up and one who discontinued 
early due to febrile neutropenia, leaving 55 patients with locally advanced or locally recurrent TGCT assessable 
for response. Seventeen patients (31%; 95% CI 19–43) had a RECIST-defined response, including 2 (3%) patients 
with a complete response. The median time to best response was 6 (range 1–23) months.
Forty of 51 patients (78%) reported symptom improvement (Table 2), including 14 of 15 patients with radi-
ological response (CR or PR). Among patients with radiological stable disease (SD), 22 of 30 patients (73%), for 
whom data was available, had symptom improvement.
The 1-, 2- and 5-years overall PFS, metastatic patients (N = 4) excluded, was 71% (95% CI 60–85), 60% (95% 
CI 48–75) and 48% (95% CI 36–65) respectively(Fig. 1).
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Follow-up. Overall 38/58 patients (66%), metastatic patients (N = 4) excluded, eventually discontinued IM 
after a median of 7.0 (range 1–80 months). The most common reason for treatment discontinuation was patient 
decision to stop (n = 14, which possibly reflect low grade chronic toxicity), followed by planned surgery (n = 10), 
toxicity (n = 7), physician’s decision (n = 5) and progression (n = 1). One patient discontinued IM because of the 
diagnosis of another tumor requiring therapy. Among the 27 patients who discontinued treatment for reasons 
other than surgery or progression, progression (either radiological progression or requirement for another line 
of therapy – i.e. surgery, other medical therapy or radiotherapy) eventually occurred 17 patients after a median 
of 12 (range 4–84) months, while 10 patients never progressed (nor required additional therapy) after a median 
follow-up to 78 (range 1–109) months, suggesting that IM was able to provide prolonged symptomatic relief at 
least in a proportion of patients. Detailed information on each patient is presented in Fig. 2.
Safety. Forty-five of 58 patients (78%), metastatic patients (N = 4) excluded, reported at least one adverse 
event with IM. The most common adverse events were edema (N = 28, 48%), fatigue (N = 29, 50%), nausea 
(N = 21, 34%) and skin rash/dermatitis (N = 7, 12%), mostly grade 1–2 (89%). Additional grade 1–2 complaints 
were diarrhea, reflux, auditory hallucinations, conjunctivitis, sexual impairment, asthenia, alopecia, cramps and 
dyspnea. Five (11%) patients had grade 3–4 toxicities, including neutropenia, acute hepatitis, facial edema, skin 
toxicity and fatigue (Table 3).
Discussion
To our knowledge, this retrospective study provides the largest case series, with long follow-up, of patients with 
locally advanced, recurrent or metastatic diffuse-type TGCT treated with IM. We confirmed that IM has activity 
in TGCT with an overall response rate of 31% in patients with locally advanced/recurrent TGCT. Interestingly all 
patients with metastatic TGCT progressed on IM, suggesting that metastatic TGCT is either a different disease or 
loses its dependency on the CSF1/CSF1R axis during malignant transformation. The main issue, is the drop-off 
rate, with more than half of the patients discontinuing therapy within a year of therapy (59%; 95% CI 29–57), in 
most cases for unclear reasons (patients decision, physician’s decision) suggesting an unfavorable efficacy/toxicity 
balance. Eleven percent of patients reported grade 3–4 toxicities, which is consistent with the rates reported with 
IM for adjuvant gastrointestinal stromal tumors (GIST) or chronic myeloid leukemia (CML)19–22.
To date, surgical resection remains the treatment of choice for diffuse-type TGCT, but is associated with high 
recurrence rates and multiple additional surgeries11. It is challenging to balance between increased morbidity 
Patients N (%)
Total 62 (100)
Median age at diagnosis (IQR), yrs. 39 (31–53)
Median time from diagnosis to start IM (IQR), 
yrs. 3.5 (1–8)
Sex
Male 23 (37)
Female 39 (63)
Tumor location
Knee 35 (56)
Ankle 11 (18)
Hip 6 (10)
Foot 4 (6)
Shoulder 1 (2)
Elbow 1 (2)
Head and Neck 2 (3)
Wrist 2 (3)
Surgery before start IM
None 15 (24)
1–2 24 (39)
3–4 13 (21)
>4 10 (16)
Median N of surgeries (range) 2 (1–9)
Median time since last surgery (range), mo. 23 (1–192)
Disease status
Locally advanced 20 (32)
Recurrence after surgery 39 (63)*
Metastatic disease 3 (5)
Table 1. Descriptive of diffuse-type TGCT patients receiving imatinib mesylate treatment. Abbreviations: 
TGCT = Tenosynovial Giant Cell tumor, IM = imatinib mesylate, N = Number of patients, mo = months, 
yrs = years. *One of the locally recurrent patients progressed to metastatic disease.
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of multiples or invasive surgeries12,23, alternative therapeutic options, and daily symptoms of the tumor. A more 
aggressive resection or other multimodality treatments, such as external beam radiation therapy, radiosynovec-
tomy and cryosurgery, may adversely affect joint function, quality of life and development of osteoarthrosis, 
which, given the young age group, are relevant factors2,24. This would justify a less invasive approach, using 
systemic therapy, provided those are associated with tumor shrinkage and, most importantly, symptomatic 
improvements25.
In the present study, age, localization and gender distribution were consistent with the literature10,24,26. The 
extent of disease in our patient group is emphasized by a disease specific survival of 90% including four meta-
static patients and 49% of patients had three or more surgeries before start IM. Similar to previous case-series, 
we calculated a 1- and 5-years PFS of 71% and 48%, metastatic patients excluded, respectively10,24,26. Because of 
heterogeneity of patients and a variety of treatments, it is debatable to compare these numbers.
The overall response rate appears higher compared to nilotinib 6% (95% CI unknown), a different tyrosine 
kinase inhibitor, with similar potency against CSF1R27. Our overall response rate 31% (95% CI 19–43, metastatic 
patients (N = 4) excluded) was consistent with our previous report on the short term results of IM 19% (95% CI 
4–34) with similar disease control rate (96% versus 93%)17. In the present study, 38 (66%) patients discontinued 
IM; 14 (37%) without subsequent treatment, of which ten patients had stable disease at final follow up. Of the 38 
patients who discontinued IM, 21 patients (55%) discontinued IM for toxicity or non-specific medical reasons. 
Parameter Patients N (%)
RECIST best response*
Complete remission 2 (4)
Partial response 15 (27)
Stable disease 36 (65)
Progressive disease 2 (4)
Overall response rate 17 (31)
Rate of disease control 53 (96)
Symptomatic response 40 (78)**
Median IM treatment duration (IQR), mo. 9.3 (5–26)
Median PFS (IQR), mo. 18 (8–55)
Table 2. Summary of imatinib mesylate efficacy in patients with locally advanced or recurrent diffuse-type 
TGCT. Abbreviations: TGCT = Tenosynovial Giant Cell tumour, IM = imatinib mesylate, N = Number 
of patients, mo = months, yrs = years, IQR = inter quartile range. Overall response rate includes complete 
remission and partial response; Rate of disease control includes complete remission, partial response and stable 
disease; Symptomatic response was indicated as present or not (40/51 = 78%). Metastatic patients (n = 4) were 
excluded. *N = 3 RECIST best response not available; **N = 9 symptomatic response not available.
Figure 1. Kaplan–Meier survival curves showing the duration of imatinib mesylate treatment (yellow line) 
and progression free survival (PFS; blue line) in patients with locally advanced or recurrent diffuse-type TGCT. 
PFS was calculated from the date imatinib mesylate was started to the date of disease progression or death. The 
shaded areas are 95% confidence intervals (CI). Over half of the patients discontinued IM within a year. The 
overall PFS after 5 years was ~50%.
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13 (62%) out of these 21 patients eventually progressed. Both stable and progressive patients can be a result of 
discontinuing IM treatment or the natural course of disease.
Newer, more specific inhibitors of CSF1R, currently only available in trial-setting such as emactuzumab 
(RG7155)28, pexidartinib (PLX3397)15,29,30, and cabiralizumab31 (FPA008, Five-Prime), have shown promising 
clinical activity on similar groups of diffuse TGCT patients in prospective clinical studies with more formal 
criteria and timelines for response assessment than this retrospective series. Emactuzumab (N = 29)16 had an 
overall response rate of 86% (two patients with a complete response) and a rate of disease control of 96%, includ-
ing a significant functional and symptomatic improvement (median follow up 12 months). Pexidartinib showed 
(N = 23)15 an overall response rate of 52% (all patients had a partial response) and a rate of disease control of 83%. 
At ASCO 2018 results of a pexidartinib placebo controlled, phase 3 study showed a significant improved overall 
response rate (39.3% vs 0%) and PROMIS physical function (4.06 vs 0.89), after a median 6 months follow up29. 
Figure 2. Response and follow up of imatinib mesylate in patients with locally advanced or recurrent diffuse-
type TGCT. NED = No evidence of disease, AWD = Alive with disease.
Patients N (%)
Variable All grades Grade 3–4
Edema/fluid retention 28 (48) 1 (2)
Fatigue 29 (50) 1 (2)
Nausea 20 (34)
Skin rash/dermatitis 7 (12) 2 (3)
Other* 15 (26) 3 (5)
Treatment status
Continued on IM 20 (34)
Stopped IM 38 (66)
Reason for stopping
Progression 1 (2)
Toxicity 7 (12)
Surgery 10 (17)
Patient choice 14 (24)
Physician decision 5 (9)
Other tumor 1 (2)
Table 3. Main toxicities associated with imatinib mesylate and reasons for discontinuation, metastatic 
patients excluded. IM = imatinib mesylate, N = Number of patients. Forty-five (78%) patients reported at 
least one adverse event with IM. *Other grade 1–2 complaints were diarrhea, reflux, auditory hallucinations, 
conjunctivitis, sexual impairment, asthenia, alopecia, cramps and dyspnea. Five (11%) patients had grade 3–4 
toxicities, including neutropenia, acute hepatitis, auditory hallucinations.
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The preliminary results with cabiralizumab (N = 22) are consistent, with radiographic response and improvement 
in pain and function in five out of 11 patients31. However, long term efficacy data have not yet been reported with 
these newer agents.
Virtually all patients treated with IM for either CML or GISTs, experience32 at least one mild or moderate 
adverse effect (grade 1–2). Toxicities of IM are determined by the disease stage and the doses used, advanced 
disease and higher doses result in more frequent and severe toxicities. Most side effects occur early in the course 
of treatment and tend to decrease in frequency and intensity in time32. We consider a 10–15% rate of grade 3–4 
toxicities in a generally benign but locally aggressive disease, such as diffuse TGCT, too high. Only 22% of patients 
did not experience any side effects.
Although target anti-cancer therapies are described as ‘well tolerated’, the perception of tolerability may vary 
in the context of a, most often, benign condition. Understanding, monitoring and managing the side effects will 
be important to optimize systemic therapy for patients with TGCT.
Discontinuation of treatment due to toxicities was seen for IM (this series), emactuzumab15 and pexidartinib16 
in 12%, 20% and 9% patients, respectively. TGCT patients might be less willing to cope with adverse event-related 
and study-related procedures. Here, we report prolonged clinical benefit and symptomatic relief, even after dis-
continuation of treatment. A similarly persistent effect was observed with monoclonal antibodies and more spe-
cific CSF1R tyrosine kinase inhibitors25. This suggest that intermittent treatment administration may be an option 
to improve long term tolerability.
The place of systemic treatment in a benign, locally aggressive disease, such as TGCT, and how to optimally 
deliver this treatment, remains unclear. More specifically, the role of CSF1R inhibitors in the peri-operative set-
ting still needs to be explored: the number of patients who underwent operation after IM in our series is too low 
to draw any conclusions. Despite limitations related to its retrospective nature, this study adds to the knowledge of 
targeting the CSF-1/CSF-1R pathway in patients with TGCT. An optimal treatment strategy should be developed 
for the patient group that benefits most from systemic therapy. The combination of a short period of treatment 
and the durable effect after discontinuation, should be pursued. It is challenging to maintain compliance for years, 
especially with, even “minor”, toxicities, in the context of a non-life-threatening disease.
So far, less or more specific tyrosine kinase inhibitors have been tested in selected patients who had inoperable, 
progressive, or recurrent disease15–17,30,31,33. These selected individuals represent a small group of severely affected 
patients that are a part of a much larger, often less complicated group of patients. The patients who would ben-
efit most from systemic therapy should be identified on the basis of molecular tumour features sensitive to that 
specific treatment34. In addition, recently an objective MR imaging-based TGCT severity classification has been 
developed35. The proposed severity classification may be helpful to identify the more aggressive TGCT subtypes 
eligible for systemic therapy or trials for novel agents.
A limitation of all, including this, clinical TGCT studies is the lack of a control group and the absence of spe-
cific and validated patient-reported outcome measures to document treatment-induced symptomatic, functional 
and economic (back to work) improvement16. Quality of life and functional forms should be implemented. These 
measures are critical endpoints in demonstrating clinical relevance and impact of treatments for benign diseases 
in which death is not a relevant outcome variable36. Clinical benefit necessitates objective measures to correlate 
with tumor reduction.
Conclusion
Identification of a biologic aggressive subgroup of diffuse TGCT, at risk of increased surgical morbidity or recur-
rent disease, should aid to decide which patients benefit most of systemic treatments. With the advent of more 
potent CSF-1R inhibitors, such as emactuzumab, pexidartinib and cabiralizumab, the role of IM in extensive 
TGCT might weaken, but may be balanced by the favorable safety profile of IM. Availability of these new com-
pounds, both in terms of registration and reimbursement, will ultimately define the prescribed drug in daily 
practice37.
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